Evaluation of a 47Sc-labeled PDGFRβ-targeting affibody for SPECT imaging and radiotherapy applications in pancreatic cancer - Top-Institutions - MDSpire

Evaluation of a 47Sc-labeled PDGFRβ-targeting affibody for SPECT imaging and radiotherapy applications in pancreatic cancer

  • By

  • Ruomeng Liu

  • Dongping Su

  • Yuhao Liao

  • Zhao Li

  • Bo Li

  • Yunming Chen

  • Qi Cao

  • Jinsong Zhang

  • Huawei Cai

  • January 5, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Nuclear Medicine
    • Oncology
    • Radiopharmaceutical Development

  • #2

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Nuclear Medicine
    • Molecular Imaging

  • #3

    Karolinska Institutet
    Karolinska Institutet

    Stockholm, N/A

    Key Differentiators

    • Nuclear Medicine
    • Radiopharmacy
    • Oncology

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Nuclear Medicine
    • Oncology
    • Molecular Imaging

  • #5

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Nuclear Medicine
    • Molecular Imaging

Original Source(s)

Evaluation of a 47Sc-labeled PDGFRβ-targeting affibody for SPECT imaging and radiotherapy applications in pancreatic cancer

  • by Ruomeng Liu, Dongping Su, Yuhao Liao, Zhao Li, Bo Li, Yunming Chen, Qi Cao, Jinsong Zhang, Huawei Cai

  • January 5, 2026

Related Content

Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch®): a systematic review

Radiotherapy plus immunotherapy with or without chemotherapy improves survival in elderly esophageal squamous cell carcinoma: a real-world comorbidity-stratified study

Fox Chase Cancer Center’s Dr. Joshua E. Meyer Named a Fellow of the American Society for Radiation Oncology

Joshua E. Meyer, MD, FASTRO, Vice Chair of Translational Research and a Professor in the Department of Radiation Oncology at Fox Chase Cancer Center, has been named a Fellow of the American Society for Radiation Oncology (ASTRO) at the organization’s 2025 Annual Meeting being held in San Francisco.

  • by

  • September 25, 2025

  • 4 min